Norges Bank Cyma Bay Therapeutics, Inc. Transaction History

Norges Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 05, 2021	SELL	$3.47 - $4.42 $1.61 Million - $2.05 Million	-463,124 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$3.94 - $4.92 $1.82 Million - $2.28 Million	463,124 New	463,124 $2.02 Million
Q4 2020 Feb 10, 2021	SELL	$5.73 - $9.03 $6.07 Million - $9.56 Million	-1,059,125 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$3.32 - $7.24 $3.52 Million - $7.67 Million	1,059,125 New	1,059,125 $7.67 Million
Q3 2020 Nov 10, 2020	SELL	$3.32 - $7.24 $2.29 Million - $4.99 Million	-688,825 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$1.41 - $4.25 $971,243 - $2.93 Million	688,825 New	688,825 $2.4 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.